SCHEMBL5652856

SCHEMBL5652856

Cc1ccc(N2CCCN(C(=O)O)C(C(C)(C)C)C2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
SLC6A9 P48067 3/20 0.41
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
KDM4E B2RXH2 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 2/20 0.39
RAB9A P51151 2/20 0.39
MAPK1 P28482 1/20 0.39
GRM1 Q13255 2/20 0.38
HRH3 Q9Y5N1 1/20 0.38
HTT P42858 2/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15205472 0.87 CHRM4 (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL27128220 0.83 GRM1 (0.52) KDM4ESMN1; SMN2ALDH1A1GRM1HPGD
SCHEMBL27131408 0.81 MAPT (0.40) KDM4ESMN1; SMN2ALDH1A1RAB9AHTT
SCHEMBL22638185 0.81 ME2 (0.51) RAB9AGRM1NPC1KMT2ACYP2C9
SCHEMBL17818499 0.80 SLC6A9 (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL25273965 0.80 GRM1 (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL20140757 0.79 GRIN2B (0.44) GRIN2BKDM4EGRM1PARP1
SCHEMBL3554487 0.77 CHRM4 (0.51) PANK3PARP1
SCHEMBL26620008 0.76 MEN1 (0.55) KDM4EALDH1A1MAPK1MAPTHPGD
SCHEMBL20142336 0.75 GRM1 (0.47) GRM1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070219234-A1 Thienopyridine Derivatives SANKYO COMPANY, LIMITED (JP) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219234-A1 Thienopyridine Derivatives RASGRP1, NRAS, HRH3 GRIN2D 1362/4885GRIN3B 1164/4885GRIN1 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.